Cortalix Awarded SNN Grant for Next-Generation ELISA

We are pleased to announce that Cortalix has been awarded a grant from the Northern Netherlands Regional Development Agency (SNN) to support our project aimed at improving VHH-based ELISAs for prostate cancer. Using our advanced VHH antibody discovery platform, we...

Cortalix acquires patents and knowhow from BiOrion

Cortalix BV acquires patents and know-how from BiOrion on its single domain antibody platform and fibrogenesis biomarker radiopharmaceuticals. With these patents and know-how, Cortalix can continue to work on 2 active clinical programs around PET imaging of...